Yield Growth Building Value with Psychedelic IP as Chart Makes Double Bottom June 10, 2020 - Baystreet.ca Historically, most of a company’s value was measured by physical assets. In 2020, that is not the case. Intellectual property – patents, trademarks, copyrights, trade secrets, etc. – is where value is calculated. Research indicates that non-tangible assets constitute 80% of an average company’s value today. In emerging markets, like that of psychedelics, getting IP in place in vital to unlocking value and positioning for future growth. This fact has not escaped The Yield Growth Corp. (CSE: BOSS)(OTCQB: BOSQF), a Vancouver-based company that has moved at light speed to cement an early position in the nascent field of medicinal psychedelics, namely psilocybin and psilocin, compounds found in so-called “magic” mushrooms. The company is a phytoceutical and consumer packaged goods company specializing in acquiring IP related to plant-based products and therapeutics that serve as cornerstones for new product development. Through its majority-owned subsidiary, NeonMind Biosciences, Yield Growth is looking to capture share in the $4.2 trillion global wellness market and a psychedelic segment forecast by Data Bridge Market Research to climb 16.3% annually to $6.9 billion by 2027. Again, IP is king here, with product as queen. Across its family of companies, Yield Growth has 14 patent applications filed, 20 products on the market, and 200 proprietary products at various stages of development. Always opportunistic, the company recently launched new hand sanitizer products in response to COVID-19 under its Urban Juve brand. NeonMind this week added to its IP portfolio, filing a U.S. provisional patent application for the invention relating to therapeutic administration of psilocybin, psilocin and any analogs thereof combined with supportive therapeutic treatment for a patient to provide weight loss benefits and treatment for related health issues. Filing in the U.S. provides NeonMind with rights protecting its IP for one year to file for patents in more than 170 countries that are members of the Paris Convention. “By most standards, magic mushrooms and related compounds were pegged only to the hippy culture, but that stigma is changing drastically,” said Penny White, CEO of Yield Growth, in a phone conversation with Baystreet.ca. “The seismic shift is owed largely to the legalization of marijuana, which enlightened consumers, lawmakers and scientists alike to the medical values and opportunity to explore new pathways for cannabinoids where traditional medicines have failed people miserably. Finally changing that paradigm has paved the way for more rapid acceptance of psilocybin therapy.” FOMO, or fear of missing out, has investors starting to pour into psychedelics for their tremendous upside potential. Psilocybin is theorized to have a litany of health benefits, including helping with weight loss, post-traumatic stress disorder, anxiety and, perhaps ironically, even drug addictions. Weight loss, of course, is a catalyst to control many deadly diseases, including cardiovascular maladies and diabetes (along with its bevy of co-morbidities), as well as reducing susceptibility to other chronic problems like high blood pressure, renal failure, urinary incontinence and more. NeonMind is at the forefront of a movement that is building momentum. The company’s provisional patent is for a proposed guided psychedelic psilocybin therapy protocol using psychotherapy prior to, during and after the psychoactive effects of the psilocybin are felt by the patient. The strategy is to help patients understand positive psychedelic experiences, which then can be integrated into everyday life to achieve the desired therapeutic outcome. This is a case of looking back to move forward. For centuries, people have used psychedelics for their divine spiritual and medical applications, albeit harvesting shrooms, consuming honey produced by bees that fed on psychotropic flowers or any other number of means. NeonMind says that microdosing psilocybin can help patients explore unresolved issues embedded in the subconscious, including examinations of pain, building self-esteem, and shedding unhealthy mechanisms related to overeating, amongst other things. Yield Growth is keeping upcoming work under its umbrella to a certain extent, as NeonMind in December contracted Translational Life Science (TLS) to design pre-clinical research of psilocybin for weight loss. The first study is expected this fall, which will provide data for a mid-stage clinical trial next year. Yield Growth owns 68% of NeonMind, which, in turn, holds 18% of TLS. Technically, the stock is making a “double bottom” at 12.5 cents, a bullish pattern that will catch the eyes of chart traders considering when BOSS hit that support level in March, it rebounded to 23.5 cents in just nine days. Legal Disclaimer/Disclosure: While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our article is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Furthermore, it is certainly possible for errors or omissions to take place regarding the profiled company, in communications, writing and/or editing. Nothing in this publication should be considered as personalized financial advice. We are not licensed under any securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this article is not provided to any individual with a view toward their individual circumstances. Baystreet.ca has been paid a fee of twenty thousand dollars for The Yield Growth Corp. advertising from the company. There may be 3rd parties who may have shares of The Yield Growth Corp. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article as the basis for any investment decision. The owner/operator of Baystreet.ca has purchased shares of The Yield Growth Corp. through a private placement and does not intend on selling any shares within 72 hours of this updated publication date after such point we reserve the right to buy and sell shares in the open market, no further notice will be given. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing Baystreet.ca, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.